A Randomized Controlled Trial of Lymphoblastoid Interferon–α in Patients With Chronic Hepatitis B Lacking Hbeag

DOI Web Site Web Site 被引用文献16件

書誌事項

公開日
1992-04
権利情報
  • http://doi.wiley.com/10.1002/tdm_license_1.1
DOI
  • 10.1002/hep.1840150405
公開者
Ovid Technologies (Wolters Kluwer Health)

この論文をさがす

説明

<jats:sec> <jats:title/> <jats:p>Ongoing hepatitis B virus replication in the presence of antibody to HBeAg can be observed in patients with active liver disease. These forms of chronic hepatitis B have been described as having a poor prognosis. We have conducted a randomized controlled trial to assess the efficacy of lymphoblastoid interferon–α in 60 patients with antibody to HBeAg and hepatitis B virus DNA-positive chronic hepatitis. Patients received 5 million U/m<jats:sup>2</jats:sup> interferon three times a week for 6 mo, or no treatment. Final evaluation 18 mo after randomization showed hepatitis B virus DNA negativity and ALT normalization in 53% of treated patients and in 17% of controls (p < 0.01). The probability of sustained hepatitis B virus DNA loss was significantly higher in treated patients than in controls (p < 0.005). Blinded histological assessment revealed improvement in 50% of treated patients compared with 33% of controls. Pretreatment hepatitis B virus DNA and aminotransferase levels and histological appearance were not predictive of response.</jats:p> <jats:p>The results of this trial indicated that marked reduction of viral replication in serum and remission of liver damage can be obtained with lymphoblastoid interferon in about 50% of patients with HBeAg antibody- and HBV DNA-positive chronic hepatitis. This rate of response is higher than that reported previously. (Hepatology 1992;15:584-589).</jats:p> </jats:sec>

収録刊行物

  • Hepatology

    Hepatology 15 (4), 584-589, 1992-04

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (16)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ